

## PR-15

**SYNTHESIS OF (2-ARYLQUINAZOLIN-4-YL)HYDRAZONES  
OF 2-HYDROXYBENZALDEHYDES AS POTENTIAL PHOSPHOINOSITIDE  
3-KINASE (IP3K $\delta$ ) AND CASEIN KINASE 2 (CK2) INHIBITORS**

**Nosova E. V.\*, Butorin I. I., Kopotilova A. E., Likhacheva M. D.**


*Chemical Technology Institute, UrFU, 620002 Ekaterinburg, 19 Mira St.*

\*E-mail: emilia.nosova@yandex.ru

**Abstract.** Phosphoinositide 3-kinase and casein kinase 2 are propitious targets for designing anticancer drugs. Idelalisib (Zydelig), fluorine-containing quinazoline derivative, is used as a medication to treat certain blood cancers, the molecule acts as inhibitor of P110 $\delta$ , the delta isoform of the enzyme phosphoinositide 3-kinase.<sup>1</sup>

(2-Phenylquinazolin-4-yl)hydrazones of 2-hydroxybenzaldehydes was previously considered as N,N,O-ligands for fluorescent zinc(II) complexes.<sup>2</sup> We developed the synthetic approach to series of new 2-arylquinazolines **1** bearing salicylidenehydrazone group at position 4 and estimated their interactions with two targets of anticancer drugs (IP3K $\delta$  and CK2) using molecular docking analysis.

2-Phenyl-6,7-difluoro derivatives **1g-j** were obtained from 4,5-difluoroantranilic acid by condensation with benzoyl chloride, 3,1-benzoxazin-4-one ring transformation under the heating with ammonium acetate, chloro-desoxygenation in quinazolin-4-one, substitution of chlorine atom with hydrazino group and reaction with the corresponding salicylic aldehyde. We developed the synthetic approach to 2-(4-fluorophenyl)derivatives **1k,l** based on condensation of anthranilamide with 4-fluorobenzaldehyde and oxidative cyclization of imine into quinazolin-4-one under the heating with copper(II)chloride.



**1:** X = F, Y = R<sup>1</sup> = H, R = H (**a**), 4-OH (**b**), 3,5-diBr (**c**);  
X = Y = R<sup>1</sup> = H, R = H (**d**), 4-OH (**e**), 3,5-diBr (**f**);  
X = R<sup>1</sup> = H, Y = F, R = H (**g**), 5-NO<sub>2</sub> (**h**),  
3,5-di-*t*Bu (**i**), 5-Cl (**j**);  
X = Y = H, R<sup>1</sup> = F, R = 3,5-di-*t*Bu (**k**), 5-Cl (**l**).

Quinazoline **1c** demonstrated better affinity to IP3K $\delta$  ( $\Delta G = -13.83$  kcal/mol) than Idelalisib ( $\Delta G = -9.92$  kcal/mol). Salicylidenehydrazone quinazolines **1i** and **1l** showed the best affinity to casein kinase 2 ( $\Delta G = -11.31$  kcal/mol and  $-12.70$  kcal/mol, correspondently).

### References

1. Furman R.R., Sharman J.P., Coutre S. E. et al. Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia. *The New England Journal of Medicine*. 2014, vol. 370, pp. 997–1007.
2. Trashakhova T. V., Nosova E. V., Slepukhin P. A. et al. 2-Hydroxybenzaldehyde (2-phenylquinazolin-4-yl)hydrazones and their Zn II complexes: Synthesis and photophysical properties. *Russ. Chem. Bull.* 2011, vol. 60, pp. 2347–2353.

*This work was supported by the Ministry of Science and Higher Education of Russian Federation, State Contract no FEUZ-2020-0058 (H687.42B.223/20).*